media – Page 181 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics

SHANGHAI, Feb. 21, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized as a 2024 Industry Top-Rated and Regional Top-Rated Company by Morningstar Sustainalytics’ Environmental, Social and Governance (ESG) Ratings, marking the fourth consecutive year the company has achieved this honor. Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with the development and implementation of responsible investment strategies. Its 2024 ESG Ratings cover more than 14,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements. WuXi Biologics ranks in the top 2% of the nearly 1,000 companies assessed in the pharmaceutical sector. Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to once again receive this honor from Morningstar Sustainalytics, which is a strong ...
- Source: drugdu
- 133
- February 23, 2024
Navigate Pharma Trade with Ease – Essential Websites & Tools for Success

The pharmaceutical trade industry is fiercely competitive, requiring constant updates on the latest market information and technological tools for better business expansion. Today, we’ll introduce some indispensable websites and practical tools to help you conduct your business more efficiently. 1.Global Trade Alert (https://www.globaltradealert.org/) Global Trade Alert is a website offering real-time tracking of global trade data, policy, and regulatory changes, helping trade professionals understand each country’s import and export policies for pharmaceutical products, market dynamics, and potential risks. 2.gov (https://www.export.gov/) Export.gov, the official website of the U.S. International Trade Administration, provides vast information on exporting, including market intelligence, export planning, and trade policies. The pharmaceutical product export guide helps trade professionals comprehend the U.S. pharmaceutical market overview and export regulations. 3.FDA (https://www.fda.gov/) The FDA, the official website of the U.S. Food and Drug Administration, provides regulations, standards, and registration requirements for various pharmaceutical products, enabling trade professionals to ensure their ...
- Source: drugdu
- 224
- February 22, 2024
Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine

Currently, mammography is the standard method for breast cancer diagnosis, but it has several limitations. The primary concern with mammograms is their lack of infallibility. False negatives can occur when normal breast tissue conceals cancer, and false positives may arise from anomalies that resemble cancer but are benign, causing unnecessary anxiety for patients. Additionally, the radiation involved in these tests could potentially contribute to the development of cancer over time. Now, a pain-free, low-cost, sensitive, radiation-free device that can detect breast cancer in urine with a sensitivity of 88.33% could bring about a shift in the diagnostic approach toward this disease. The Blue Box Biomedical Solutions (Barcelona, Spain) has developed an affordable, user-friendly, and portable device that can detect breast cancer using a urine sample. This device, known as the Blue Box, employs an innovative eNose (electronic nose) to detect the smell of urine. It features a chemical sensor array ...
- Source: drugdu
- 146
- February 22, 2024
Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step

Hepatitis B, a significant global health concern, is responsible for chronic liver diseases like cirrhosis and liver cancer which is one of the most common cancers worldwide. The challenge with hepatitis B is that most carriers are asymptomatic, remaining unaware of their infection, which can lead to its unintentional spread. Thus, early diagnosis is vital to halt the spread, initiate timely treatment, and reduce the risk of liver complications primarily caused by the hepatitis B virus. However, conventional tests for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) are complex, requiring specialized skills and large, expensive machine-based assays typically found in major hospitals. To overcome the problem of inadequate access to screening for Hepatitis B, researchers have developed a wireless, point-of-care test for the Hepatitis B Virus that can make diagnosis simpler and faster. Researchers from Chulalongkorn University (Bangkok, Thailand) have developed a testing kit that enables ...
- Source: drugdu
- 97
- February 22, 2024
WuXi Advanced Therapies’ Philadelphia Site Approved by FDA to Start Manufacturing Iovance’s Melanoma T-cell Therapy

Don Tracy, Associate Editor Amtagvi is the first one-time, individualized T-cell therapy approved by the FDA for any solid tumor cancer. WuXi Advanced Therapies announced that it has officially received approval from the FDA to begin analytical testing and manufacturing of Amtagvi (lifileucel), Iovance Biotherapeutics’ recently approved treatment for advanced melanoma. According to a company press release, the treatment is a tumor-derived autologous T cell immunotherapy, specifically developed for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody. This also marks the first one-time, individualized T cell therapy to be approved by the FDA for any solid tumor cancer. “We congratulate Iovance on this major milestone in their quest to address unmet patient needs in the treatment of advanced melanoma. WuXi ATU has partnered with Iovance since 2015, and we are thrilled to help them through each step of the drug development pipeline – from ...
- Source: drugdu
- 172
- February 22, 2024
Adverse Event Prompts FDA Hold on Tests of Drug in Atopic Dermatitis & Asthma

The FDA clinical hold follows a a report of liver failure that may be associated with zelnecirnon, an experimental Rapt Therapeutics drug. The biotech notes that no other patient has experienced liver problems and this safety signal has not been seen in any other tests of the molecule. By FRANK VINLUAN Rapt Therapeutics aim to bring patients oral alternatives to injectable or infused immunology medications has hit a setback. A Rapt drug candidate in mid-stage clinical development in atopic dermatitis and asthma has been placed under an FDA clinical hold after a serious adverse event reported in a study participant, the company announced Tuesday. The patient, a participant in the atopic dermatitis study, experienced liver failure. According to Rapt, the cause of the liver failure is unknown but has been characterized as potentially related to the company’s experimental drug, zelnecirnon. South San Francisco-based Rapt said the FDA verbally notified the ...
- Source: drugdu
- 157
- February 22, 2024
Sperogenix Therapeutics introduced for US$124 million! New drug for Duchenne muscular dystrophy planned to be included in priority review

Today (February 18), the official website of the Center for Drug Evaluation (CDE) of the NMPA of China announced that the vamorolone oral suspension applied by Sperogenix Therapeutics is scheduled to be included in the priority review, and the indication is Duchenne muscle aged 4 years and above. Public information shows that this is a new rare disease drug introduced by Sperogenix Therapeutics from Santhera Pharmaceuticals for US$124 million. It has been approved to treat DMD in the United States and the European Union. It is reported that vamorolone has achieved positive results in the key clinical study VISION-DMD and three open-label studies and expansion studies. In the VISION-DMD study, compared with placebo, the vamorolone group reached the primary endpoint after 24 weeks of treatment, and the difference in the time required from lying to standing was statistically significant compared with the placebo group. Additionally, male patients treated with vamorolone ...
- Source: drugdu
- 136
- February 22, 2024
AstraZeneca’s Tagrisso combination approved by FDA for advanced lung cancer

AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) in combination with chemotherapy to treat a subset of advanced lung cancer patients. The epidermal growth factor receptor-mutated (EGFR)-tyrosine kinase inhibitor has specifically been authorised for use alongside chemotherapy in adults with locally advanced or metastatic EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). An estimated 200,000 people in the US are diagnosed with lung cancer each year and NSCLC accounts for up to 85% of all lung cancer cases. Approximately 15% of NSCLC patients in the US have an EGFRm, with this population “particularly sensitive” to treatment with an EGFR-tyrosine kinase inhibitor that blocks the cell-signalling pathways that drive the growth of tumour cells, AZ said. The FDA’s decision was supported by positive results from the late-stage FLAURA2 trial, which randomised more than 500 patients with locally advanced or metastatic EGFRm NSCLC to receive the ...
- Source: drugdu
- 133
- February 22, 2024
ABPI publishes new prescribing support guide for healthcare professionals

The Association of the British Pharmaceutical Industry (ABPI) has published a new guide to how the pharmaceutical industry can support healthcare professionals (HCPs) with prescribing decisions. The report, No More, No Less: a Guide to the Appropriate Prescribing of Medicines and the Role of Industry, highlights the responsibilities that pharmaceutical companies have to ensure they provide accurate information to support high-quality healthcare. Every year in the UK, over one billion medicines are prescribed and dispensed from more than 18,000 preparations licenced for use by the Medicines and Healthcare products Regulatory Agency. The current resources available for pharmaceutical companies to support the quality, safety and efficacy of medicine include the Summary of Product Characteristics, medical information and pharmacovigilance expertise, as well as medical advisers. In the UK, most pharmaceutical companies provide a Medical Information Service (MIS) for HCPs, patients and the public via telephone or email. In addition, MIS personnel or ...
- Source: drugdu
- 104
- February 22, 2024
Recombinant Herpes Zoster Vaccine Independently Developed by Shanghai Institutes for Biological Products of China Receives Clinical Trial Approval Notice

On February 20, the recombinant herpes zoster vaccine, a Class I new drug independently developed by Shanghai Institutes for Biological Products of China, received a notice of approval for clinical trial from the State Drug Administration. Herpes zoster is a common viral infectious disease caused by the reactivation of varicella-zoster virus latent in the human sensory ganglia, with severe nerve pain and skin herpes as the main symptoms. According to relevant data, there are about 1.56 million new cases of herpes zoster in people aged 50 years and above every year in China. Herpes zoster and its complications seriously affect the work and life of patients. Vaccination against herpes zoster is an important measure for the prevention of herpes zoster and postherpetic neuralgia, but at present there are limited varieties of herpes zoster vaccine available in China. Shanghai Institutes for Biological Products (SIBI) has independently developed a recombinant herpes zoster ...
- Source: drugdu
- 91
- February 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.